Contraindicated in:
Use Cautiously in:
Derm: rash (↑ in patients with cystic fibrosis), ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, urticaria.
GI: diarrhea, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), constipation, drug-induced hepatitis, nausea, vomiting.
GU: interstitial nephritis, renal failure.
Hemat: bleeding, leukopenia, neutropenia, thrombocytopenia.
Local: pain, phlebitis at IV site.
Neuro: confusion, dizziness, headache, insomnia, lethargy, SEIZURES (HIGHER DOSES).
Misc: fever (↑ in cystic fibrosis patients), hemophagocytic lymphohistiocytosis, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND SERUM SICKNESS), superinfection.
Drug-Drug:
(Generic available)
Appendicitis/Peritonitis
Renal Impairment
Nosocomial Pneumonia
Renal Impairment
Skin and Skin Structure Infections, Gynecologic Infections, and Community-Acquired Pneumonia
Renal Impairment
Spectrum:
Therapeutic Classification: anti-infectives
Pharmacologic Classification: extended spectrum penicillins
Absorption: IV administration results in complete bioavailability.
Distribution: Widely distributed. Enters CSF well only when meninges are inflamed.
Metabolism/Excretion: Piperacillin (68%) and tazobactam (80%) are mostly excreted unchanged by the kidneys.
Half-life: Adults: 0.71.2 hr; Children (6 mo12 yr): 0.70.9 hr; Infants (25 mo): 1.4 hr.
NDC Code*